Rio Tinto Reports Strong Q2 Iron Ore Sales, Maintains 2026 Production Outlook 
NY Times Challenges Trump Administration Subpoenas Over Air Force One Report 
Taiwan Mangoes Head to Europe as Premium Fruit Exports Expand 
Stripe, Advent Offer Over $53 Billion to Acquire PayPal in Major Fintech Deal 
Jamie Dimon Warns Anthropic's Mythos AI Poses National Security Risks 
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline 
xAI Sues Man for Allegedly Using Grok to Generate AI Child Abuse Deepfakes 
ASML Raises 2026 Outlook as AI Chip Demand Lifts Q2 Earnings 
Sodexo Unveils Shift & Grow 2030 Strategy, Targets Over 5% Revenue Growth by Fiscal 2030 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
Uber to Acquire Delivery Hero in $14.8 Billion Deal to Expand Global Food Delivery Business 
Airbus Signs Cloud Deal With Scaleway to Power Secure AI and Defense Applications 
SpaceX Stock Falls Below IPO Price as Investors Weigh Losses and Lockup Expiry 
BHP Q4 Iron Ore Output Rebounds as Copper Prices Boost Revenue 
SK Hynix Stock Soars as AI Memory Demand Outlook Fuels Chip Rally 
Apple Intelligence Cleared for China as Alibaba and Baidu AI Power iPhone Features 
UBS Boosts China Tech Bets, Adds Kuaishou and Meituan to Focus List 
NEW ORLEANS, Jan. 29, 2016 -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until March 14, 2016 to file lead plaintiff applications in a securities class action lawsuit against Esperion Therapeutics, Inc. (Nasdaq:ESPR), if they purchased the Company’s securities between August 18, 2015 through September 28, 2015, inclusive (the “Class Period”). This action is pending in the United States District Court for the Eastern District of Michigan.
What You May Do
If you purchased shares of Esperion and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn ([email protected]). If you wish to serve as a lead plaintiff in this class action, you must petition the Court by March 14, 2016.
About the Lawsuit
Esperion and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
The alleged false statements and omissions include, in part, that: (i) there was no clear path to approval for ETC-1002, a once-daily small molecule designed to lower LDL-cholesterol levels while avoiding the side effects associated with other LDL-cholesterol lowering therapies on the market; (ii) the FDA had encouraged Esperion Therapeutics to initiate a cardiovascular outcomes trial (“CVOT”); and (iii) completion of a CVOT could be necessary prior to approval of ETC-1002.
About Kahn Swick & Foti, LLC
KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.
To learn more about KSF, you may visit www.ksfcounsel.com.
Contact: Kahn Swick & Foti, LLC Lewis Kahn, Managing Partner [email protected] 1-877-515-1850 206 Covington St. Madisonville, LA 70447
